Arcutis Biotherapeutics, Inc.
General ticker "ARQT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.2B (TTM average)
Arcutis Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 9.4%.
Estimated limits based on current volatility of 3.1%: low 27.20$, high 28.96$
Factors to consider:
- Earnings expected soon, date: 2026-10-27 amc
- Total employees count: 354 (+3.5%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Limited operating history, Commercialization failure, Capital requirements, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [19.67$, 43.60$]
- 2026-12-31 to 2027-12-31 estimated range: [16.39$, 37.06$]
Financial Metrics affecting the ARQT estimates:
- Positive: with PPE of -207.5 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.15 <= 2.37
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -0.82 <= -0.14
- Negative: -1.30 < Inventory ratio change, % of -1.21
- Positive: Interest expense per share per price, % of 0.33 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ARQT quotes
Long-term ARQT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $59.61MM | $196.54MM | $376.07MM |
| Operating Expenses | $300.71MM | $324.94MM | $388.30MM |
| Operating Income | $-241.10MM | $-128.40MM | $-12.23MM |
| Non-Operating Income | $-17.93MM | $-10.99MM | $-2.74MM |
| Interest Expense | $29.71MM | $27.17MM | $12.08MM |
| R&D Expense | $110.58MM | $76.42MM | $77.05MM |
| Income(Loss) | $-259.03MM | $-139.39MM | $-14.97MM |
| Taxes | $3.11MM | $0.65MM | $1.17MM |
| Net Income(Loss)* | $-262.14MM | $-140.04MM | $-16.14MM |
| Stockholders Equity | $88.67MM | $157.54MM | $189.48MM |
| Inventory | $13.13MM | $14.53MM | $22.63MM |
| Assets | $341.37MM | $348.89MM | $432.97MM |
| Operating Cash Flow | $-247.06MM | $-112.16MM | $-5.62MM |
| Capital expenditure | $0.43MM | $0.14MM | $0.69MM |
| Investing Cash Flow | $180.23MM | $28.82MM | $-30.25MM |
| Financing Cash Flow | $101.32MM | $66.20MM | $6.97MM |
| Earnings Per Share** | $-3.78 | $-1.16 | $-0.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.